HT-0712

HT-0712

160px
Systematic (IUPAC) name
(3R,5R)-5-(3-(cyclopentyloxy)-4-methoxyphenyl)-3-(3-methylbenzyl)piperidin-2-one
Identifiers
CAS Number	617720-02-2
Synonyms	HT-0712, IPL 455,903
Chemical data
Formula	C25H31NO3
Molar mass	393.53 g/mol[[]]

HT-0712 is an experimental cognitive enhancing drug (nootropic) which is currently undergoing clinical trials. It is currently being licensed by Helicon Therapeutics in Cleveland, Ohio. It was originally discovered and tested as part of a preclinical anti-inflammatory program by Inflazyme Pharmaceuticals.

Mechanism of action

HT-0712 appears to act as a PDE4 inhibitor, thereby increasing cAMP levels. When cAMP levels are increased in neurons, this may trigger activation of cAMP response element-binding proteins (CREB). CREBs are transcription factors involved in the formation of long-term memory.

The side effects of the drug are not yet fully known.

Medical use

Middle-aged people, seniors, and possibly those suffering from dementia, who have a hard time remembering everyday events, can possibly benefit from this drug.

Performance enhancing use

Many students may be inclined to use nootropics for school and college life for exams and finals. This could also be an effective alternative or adjunctive to the use of caffeine as a study aid.

References

United States Patent 20040224316

External links

• Helicon Therapeutics
• PDF file regarding Helicon's commencement of Phase I trials
• News article on HT-0712